BME:OHLA
BME:OHLAConstruction

3 European Stocks Possibly Trading Below Their Intrinsic Value By Up To 39.9%

The European stock market has recently experienced a downturn, with the pan-European STOXX Europe 600 Index falling by 2.21% amid concerns over inflated AI stock valuations and receding expectations for a U.S. interest rate cut. Despite these challenges, business activity in the eurozone continues to expand steadily, presenting potential opportunities for investors seeking stocks that may be undervalued relative to their intrinsic value. In this context, identifying stocks that are trading...
BME:CASH
BME:CASHCommercial Services

Prosegur Cash And 2 European Stocks That Could Be Trading Below Their Estimated Value

Amid renewed concerns over inflated AI stock valuations and receding expectations for a U.S. interest rate cut, European markets have seen a downturn, with major indices like the STOXX Europe 600 Index ending lower. In such an environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors looking to navigate these challenging market conditions effectively.
BME:EDR
BME:EDRHospitality

eDreams ODIGEO (BME:EDR): Assessing Valuation After Guidance Cut and Shifting Growth Outlook

eDreams ODIGEO (BME:EDR) lowered its earnings guidance for 2026 and 2027, citing slower growth in its prime membership base and the effects of a shift toward flexible payment plans for subscribers. See our latest analysis for eDreams ODIGEO. eDreams ODIGEO’s share price has tumbled sharply, down 52% for the month and 59% year-to-date, reflecting fading momentum as investors digest the company’s lower earnings outlook and shifting growth profile. Despite a spike in recent net profit, the...
BME:GRF
BME:GRFBiotechs

Grifols (BME:GRF): Assessing Valuation After a Volatile Year in European Pharma

Grifols (BME:GRF) shares have moved recently, capturing attention after an extended stretch of volatility. Investors are weighing near-term developments as they consider a changing backdrop for the pharmaceutical sector in Europe. See our latest analysis for Grifols. After a turbulent year marked by sharp swings, Grifols’ 8.2% share price return since January stands out, especially as this rise has come despite recent negative momentum, including a 17.3% drop over the last three months and...
BME:SLR
BME:SLRRenewable Energy

Solaria Energía (BME:SLR) Surges After Net Income Jumps on Higher Revenue—Is Profitability the New Growth Engine?

Solaria Energía y Medio Ambiente has released its earnings results for the nine months ended September 30, 2025, reporting €258.91 million in revenue and €141.67 million in net income, both sharply higher compared to the previous year. Despite a slight decline in sales, the company achieved a very large year-on-year increase in net income, highlighting a marked improvement in profitability. We'll examine how Solaria's surge in net income, amid higher revenue, affects the company's investment...
BME:IBE
BME:IBEElectric Utilities

Iberdrola (BME:IBE) Valuation in Focus After Renewable Hydrogen Deal With IFF

Iberdrola (BME:IBE) is gaining attention after partnering with IFF to provide renewable electricity for a new green hydrogen plant at IFF’s fragrance ingredients facility in Spain. This collaboration highlights Iberdrola’s growing presence in industrial decarbonization initiatives. See our latest analysis for Iberdrola. Iberdrola’s headline-grabbing push into green hydrogen comes as its stock shows clear momentum, with a 7.3% 1-month share price return and 32.8% share price return...